Michael Gladstone - 23 May 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Reporting relationship: Director
Issuer ticker: DAWN
Reported as of: 23 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2024, 18:17:45 UTC
Prior SEC filing: 26 Jun 2023
Next SEC filing: 10 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Charles N. York II, as Attorney-in-Fact

Key filing fact

Michael Gladstone filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 28 May 2024.

Key facts

This page summarizes Michael Gladstone's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2024, 18:17.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Award

Transaction value: $0
Shares: +32,335
Change %
Price: $0.000000
Shares after: 32,335
Date: 23 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,335
Exercise price: $13.87
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.